These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 29695020)
1. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia. Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020 [TBL] [Abstract][Full Text] [Related]
2. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460 [TBL] [Abstract][Full Text] [Related]
3. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets. Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354 [TBL] [Abstract][Full Text] [Related]
4. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets. Hughes CE; Finney BA; Koentgen F; Lowe KL; Watson SP Blood; 2015 Jan; 125(1):144-54. PubMed ID: 25352128 [TBL] [Abstract][Full Text] [Related]
5. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice. Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137 [TBL] [Abstract][Full Text] [Related]
6. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets. Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114 [TBL] [Abstract][Full Text] [Related]
7. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. Mori J; Pearce AC; Spalton JC; Grygielska B; Eble JA; Tomlinson MG; Senis YA; Watson SP J Biol Chem; 2008 Dec; 283(51):35419-27. PubMed ID: 18955485 [TBL] [Abstract][Full Text] [Related]
8. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2. Zhi Z; Jooss NJ; Sun Y; Colicchia M; Slater A; Moran LA; Cheung HYF; Di Y; Rayes J; Poulter NS; Watson SP; Iqbal AJ J Thromb Haemost; 2022 Apr; 20(4):936-950. PubMed ID: 34936188 [TBL] [Abstract][Full Text] [Related]
9. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766 [TBL] [Abstract][Full Text] [Related]
10. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand. Martin EM; Clark JC; Montague SJ; Morán LA; Di Y; Bull LJ; Whittle L; Raka F; Buka RJ; Zafar I; Kardeby C; Slater A; Watson SP J Thromb Haemost; 2024 Jan; 22(1):271-285. PubMed ID: 37813196 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry. Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424 [TBL] [Abstract][Full Text] [Related]
12. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI. Ozaki Y; Suzuki-Inoue K; Inoue O J Thromb Haemost; 2009 Jul; 7 Suppl 1():191-4. PubMed ID: 19630798 [TBL] [Abstract][Full Text] [Related]
13. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Gitz E; Pollitt AY; Gitz-Francois JJ; Alshehri O; Mori J; Montague S; Nash GB; Douglas MR; Gardiner EE; Andrews RK; Buckley CD; Harrison P; Watson SP Blood; 2014 Oct; 124(14):2262-70. PubMed ID: 25150298 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480 [TBL] [Abstract][Full Text] [Related]
15. CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo. Alshahrani MM; Yang E; Yip J; Ghanem SS; Abdallah SL; deAngelis AM; O'Malley CJ; Moheimani F; Najjar SM; Jackson DE Blood; 2014 Oct; 124(15):2431-41. PubMed ID: 25085348 [TBL] [Abstract][Full Text] [Related]